Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28.

This review provides a broad overview of the biology of OX40, and the intracellular signals from OX40, that impact many aspects of immune function, and have promoted OX40 as one of the most prominent costimulatory molecules known to control T cells.

The tumour necrosis factor receptor OX40 (CD134) is activated by its cognate ligand OX40L (CD134L, CD252) and functions as a T cell co-stimulatory molecule. OX40-OX40L interactions have been proposed as a potential therapeutic target for treating autoimmunity.

OX40L is the ligand for OX40 (also known as CD134 or TNFRSF4) and is stably expressed on many antigen-presenting cells such as DC2s (a subtype of dendritic cells), [1] macrophages, [2] and activated B lymphocytes.

Reagents that interfere with the binding of OX40 to OX40L have been shown to inhibit T cell responses and pathogenic symptoms in a number of immune based diseases. Conversely reagents that augment OX40 signals have now shown therapeutic efficacy in models of cancer.

OX40 and its binding ligand OX40L (CD134L; TNFSF4; CD252) are novel immune therapeutic targets that augment the immune response. The gene for OX40 is located on chromosome 1p36 [4, 5]. OX40 expression usually peaks around 24–72 h after antigenic stimulation of the T cell receptor (TCR) by the major histocompatibility complex (MHC) [6–8 ...

OX40 is a type 1 transmembrane glycoprotein, reported nearly 30 years ago as a cell surface antigen expressed on activated T cells. Since its discovery, it has been validated as a bone fide costimulatory molecule for T cells and member of the TNF receptor family.

So, we reviewed the OX40 and its ligand (OX40L) function in cancer, clinical trials with OX40/OX40L and the correlation between OX40/OX40L and other immune checkpoints to add more ideas to tumor feasible treatment.

2004年6月1日 · In vivo blockade of OX40 signalling specifically suppresses the function of recently activated autoantigen-specific T cells, leading to inhibition of autoimmune disease without severe ...

2020年3月1日 · This review discusses the biology of OX40 and OX40L and summarizes the impact of the OX40–OX40L interaction on T cell subsets to provide a comprehensive understanding of anti-OX40 mAbs-based therapy.